777 Initial clinical characterization of novel proximal biomarkers for NX-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced malignancies
Sarah Whelan(Nurix (United States)), Janine Powers(Nurix (United States)), Ruth Plummer(National Health Service), Jordan Ye(Nurix (United States)), Anja Williams(Sarah Cannon Research Institute), Sarah P. Blagden(Churchill Hospital), Adam Sharp(Institute of Cancer Research), Ganesh Cherala(Nurix (United States)), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Matthew Krebs(Christie's), Daniel Hochhauser(Royal London Hospital), JEFF EVANS(University of Glasgow), Katherine Jameson(Nurix (United States)), Christopher Karim(Nurix (United States)), Timothy Ingallinera(Nurix (United States)), Simon Pacey(Royal Marsden NHS Foundation Trust)
Cited by 2
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k